Eurofins-Cerep SA (FR:ALECR) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Eurofins-Cerep SA reported a decrease in revenue for the first semester of 2024, down by 7.68% from the previous year, amid a contracting drug discovery market. Despite this, the company saw a positive financial result from cash investments and exchange rates, as well as progress in R&D with new pharmacological test applications and a biophysics platform for drug research. Looking ahead, the firm anticipates that renewed and developing contracts will mitigate turnover declines in the latter half of 2024.
For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.